Expand all sections

Durvalumab

Imfinzi

Extended indication Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment
Therapeutic value No estimate possible yet
Registration phase Registered

Product

Active substance Durvalumab
Domain Oncology
Reason of inclusion Indication extension
Main indication Cervical cancer
Extended indication Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer​ who are candidates for systemic therapy, followed by maintenance treatment with: - as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) - combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
Proprietary name Imfinzi
Manufacturer AstraZeneca
Mechanism of action PD-1 / PD-L1 inhibitor
Route of administration Intravenous
Budgetting framework Intermural (MSZ)

Registration

ATMP No
Submission date 2024
Expected Registration September 2024
Orphan drug No
Registration phase Registered

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

Patient volume

149 - 155

Market share is generally not included unless otherwise stated.
References NKR (1); Advies - vergoed dostarlimab (Jemperli®) voor de behandeling van baarmoederkanker. Zorginstituut. 2024 (2).
Additional remarks Jaarlijks worden ruim 2.000 nieuwe gevallen van endometriumcarcinoom gediagnosticeerd (1). Volgens de budget impactanalyse van de vergoeding van dostarlimab voor dezelfde indicatie als dit middel wordt een patiëntvolume van 149 tot 155 per jaar geschat (2).

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.